Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $11.00 Average Price Target from Analysts

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) have earned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $11.00.

A number of equities research analysts have weighed in on the stock. Morgan Stanley lifted their price target on shares of Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Friday, June 21st. Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, July 18th. They set an “outperform” rating and a $14.00 target price on the stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Large investors have recently bought and sold shares of the business. Quarry LP acquired a new position in Centessa Pharmaceuticals in the fourth quarter worth $48,000. China Universal Asset Management Co. Ltd. increased its position in Centessa Pharmaceuticals by 371.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock valued at $51,000 after acquiring an additional 5,037 shares in the last quarter. EntryPoint Capital LLC acquired a new position in shares of Centessa Pharmaceuticals during the first quarter worth approximately $109,000. Jump Financial LLC bought a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at approximately $114,000. Finally, Trexquant Investment LP acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $114,000. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $11.40 on Friday. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -8.03 and a beta of 1.40. The business has a 50 day moving average price of $9.50 and a 200 day moving average price of $9.75. The company has a quick ratio of 10.37, a current ratio of 10.37 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a twelve month low of $5.15 and a twelve month high of $12.45.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. Research analysts predict that Centessa Pharmaceuticals will post -1.62 earnings per share for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.